| Bioactivity | SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect[1]. |
| Target | IC50: 35.6 nM (SRPK1), 98 nM (SRPK2) |
| Invitro | SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout[1]. SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing[1]. Animal Model: |
| Name | SRPKIN-1 |
| CAS | 2089226-94-6 |
| Formula | C27H21FN2O3S |
| Molar Mass | 472.53 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture) |
| Reference | [1]. Hatcher JM, et al. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol. 2018 Apr 19;25(4):460-470.e6. |
SRPKIN-1
CAS: 2089226-94-6 F: C27H21FN2O3S W: 472.53
SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.